Israeli-based digital health company UltraSight has received CE Mark for its new artificial intelligence (AI) guidance cardiac ultrasound software.
The new technology allows healthcare specialists to capture diagnostic quality ultrasound images of the heart.
Go deeper with GlobalData
By 2023, this is expected to increase detection of cardiovascular diseases (CVD) as well as patient access to cardiac imaging and optimised cardiac care across Europe.
By connecting with ultrasound devices that are already available on the market, the new software can be used at the point of care, including in clinics, ambulances, community hospitals, and remote and rural areas.
The software also provides real-time instructions to operators for the process of capturing high-quality diagnostic images.
UltraSight stated that the AI neural network predicts the ultrasound probe’s position from the ultrasound video stream.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIt then directs users on how to manoeuvre the ultrasound probe to obtain diagnostic quality cardiac ultrasound images.
The new AI-driven software is also indicated for use in two-dimensional transthoracic echocardiography (2D-TTE) for adult patients.
UltraSight CEO Davidi Vortman said: “UltraSight was founded with the intention to apply the power of machine learning in imaging and put the ability to scan patients into the hands of physicians everywhere.
“By empowering more medical professionals to accurately scan patients, we will have faster and greater detection of CVD across the continent.
“This is not only a momentous occasion for UltraSight as a company, but it brings us one step closer to helping the millions of people in Europe who suffer from CVD.”
The company received CE Mark for its AI-driven technology following data obtained from a clinical study, which was conducted at the Sheba Medical Center, Israel, using the Philips Lumify ultrasound device.
In the trial, UltraSight’s new AI software was evaluated and confirmed to be effective in instructing healthcare professionals to obtain diagnostic quality cardiac images in 100% of patients.
